Montana Biotech

Sorry, we couldn't find any posts. Please try a different search.

Sirna’s move clouds Colorado’s biotech scene

Sirna announced it was moving its headquarters to San Francisco because it needed to be closer to investment bankers, venture capitalists and buy-side analysts.

Biotech company, Corixa Corp. looking for money to expand Hamilton operation

"What you’ve got is big for the community and big for Montana, but it also represents what we like about biotech in Montana," Schweitzer said. "You’re one of the wheels of the buggy and we need to keep you on. We’re not going to let you slip away."

Changing Mindset Critical for Arizona Bioscience Success, Study Advises

In synchronizing their resources and priorities with local technology enterprises, they can form the interconnections that foster knowledge transform, collaboration, and support that cannot easily be replicated by other regions.

Bioscience industry could grow in Idaho – Hundreds gather for glimpse of things to come

"Don’t ever assume there is a shortage of capital," Burrill said. "Capital is available for good ideas — your job is to find them."

Where VCs Fear To Tread : Angel investors are filling a critical gap by providing early backing for biotechs

While individuals have always played a key role in funding biotech startups, today’s angels represent a new breed — one that bears striking similarities to venture capitalists.

In Spokane, a biotech scramble

Spokane’s Gonzaga University may be most widely recognized for its nationally ranked men’s basketball team, but the private liberal arts school is aggressively positioning itself to be prominent in another field: Biotechnology research.

Governor Schweitzer Hails New Montana Bioscience Trade Association

"Montana’s BioScience industry is steadily developing," said Montana’s Governor Brian Schweitzer.

Banking on biotech – Debate rages as Colorado joins other states seeking high-tech centers

In fact, there is increasing evidence that the biotech industry may converge with nonbiological technologies into a new and advanced industrial identity as science and business increase their creative collisions. No state or region looking toward their economic future will want to sit on the sidelines.

Venture capital will tell its story – A study questions whether policymakers understand the role the industry plays in medical breakthroughs.

Federal allocations to research and development are likely to be "on the chopping block" as Congress looks to trim spending, Heesen said.

Entrepreneurs improve quality of life through Biotech development but need VC to succeed

"Without venture capital investment, there would be no innovation in biomedical technology," said David Goodman of the Weinberg Group and co-author of the report. "The research would die on the vine at universities and other research labs."